title: FDA approves tofacitinib for rheumatoid arthritis.
authors.forename: Kate
authors.initials: K
authors.lastname: Traynor
mesh_terms: D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D051544:Cytochrome P-450 CYP3A; D065692:Cytochrome P-450 CYP3A Inhibitors; D017277:Drug Approval; D006801:Humans; D010880:Piperidines; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D018501:Antirheumatic Agents; D065692:Cytochrome P-450 CYP3A Inhibitors; D010880:Piperidines; D011743:Pyrimidines; D011758:Pyrroles; C479163:tofacitinib; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human